HALOZYME THERAPEUTICS, INC. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Amount
HALOZYME THERAPEUTICS, INC. (HALO) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Amount of $59.83 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-17.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment · last filed 2026-02-17
- HALOZYME THERAPEUTICS, INC. effective income tax rate reconciliation, nondeductible expense, research and development, amount for fiscal 2025 was $59.83M.
- HALOZYME THERAPEUTICS, INC. effective income tax rate reconciliation, nondeductible expense, research and development, amount for fiscal 2024 was $0.00.
- HALOZYME THERAPEUTICS, INC. effective income tax rate reconciliation, nondeductible expense, research and development, amount for fiscal 2023 was $0.00.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Amount 12 month |
|---|---|
| 2025-12-31 | $59.83M 10-K · filed 2026-02-17 |
| 2024-12-31 | $0.00 10-K · filed 2026-02-17 |
| 2023-12-31 | $0.00 10-K · filed 2026-02-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |